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Abstract
Background: Determining the relationship between age and Alzheimer’s disease (AD) presentation is
important to improve understanding and provide better patient services.
Methods: We used AD patient data (N=7815) from the National Alzheimer Coordinating Center
database and multinomial logistic regression to investigate presentation age and first cognitive /
behavioral symptoms.
Results: The odds of having a non-memory first cognitive symptom (including impairment in
judgment and problem solving, language and visuospatial function) increased with younger age
(p<0.001, all tests). Compared with apathy/withdrawal, the odds of having depression, and “other”
behavioral symptoms increased with younger age (p<0.02, both tests), whereas the odds of having
psychosis and no behavioral symptom increased with older age (p<0.001, both tests).
Conclusions: There is considerable heterogeneity in the first cognitive / behavioral symptoms
experienced by AD patients. Proportions of these symptoms change with age with patients
experiencing increasing non-memory cognitive symptoms and more behavioral symptoms at
younger ages.
Key words: Alzheimer’s disease, clinical neurology history, first symptoms, cognition, behavior,
neuropsychology, age
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1. Introduction
The prototypical evolution of symptoms in Alzheimer’s disease (AD) begins with episodic memory
loss followed by impairment in other cognitive and behavioral domains [1, 2]. However, less typical,
non-memory presentations of AD have been recognized and include patients with visuospatial
dysfunction, visuoperceptual dysfunction, dyspraxia, executive dysfunction, literacy problems and
language problems [1-6].
There is evidence from small studies that atypical AD presentations tend to occur at younger ages of
onset [4, 7, 8] or are seen in high proportions in younger group studies [9]. Studies assessing the
relationship between onset age and first symptoms often dichotomize subjects into early onset
(before 65 years) or late onset disease (65 years and above). Such analyses have shown that around
one-third of early onset AD subjects present with non-memory symptoms including apraxia and
visuospatial dysfunction, aphasia and other language dysfunction, and agnosia [7]. Although the 65
year age cut-off can be useful, it is arbitrary and patterns of predominant first symptoms may vary
more gradually with increasing age. An alternative analytical approach is to divide patients into
groups based on neuropsychological profiles and assess between-group differences in demographics
or other features including onset age [10] or brain atrophy phenotype [11, 12]. Although such
studies have revealed differences in AD subgroups and demonstrate the underlying heterogeneity of
AD features, many subjects tend to be excluded from such analyses as they fall outside these groups
by exhibiting characteristics of neither or both. As such, groups defined in this way may be extremes
on a continuum of disease presentations [9, 13, 14].
Since much of the research relating age to AD presentation is single-site or using relatively small
sample sizes [4, 7-9], there is a need to demonstrate heterogeneity in larger, less-selected multi-site
patient samples to produce more precise estimates of age – AD presentation relationship. Further,
those with early onset AD have been shown to have a longer disease duration prior to diagnosis [7,
15], likely in part due to misdiagnosis [16], making the understanding of the different presentations
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in AD and how these relate to age extremely important for improving services offered to younger
patients.
The aim of this study was to assess the proportions of first predominant reported cognitive and
behavioral symptom according to presentation age in a large, multi-site and unselected sample of
patients with a clinical diagnosis of AD. We further assessed neuropsychological test performance to
test the hypothesis that age influences psychometric impairments in a manner congruent with
reported symptoms. Our hypotheses were that: 1) patients presenting at younger ages were more
likely to have a first symptom in a non-memory cognitive domain; 2) younger presenting patients
were more likely to experience behavioral symptoms.
2. Methods
2.1. Subjects
We included subjects from the National Alzheimer’s Coordinating Center (NACC) dataset
(http://www.alz.washington.edu/). NACC developed and maintains a database of standardized
clinical research data collected from 34 past and present NIA-funded Alzheimer’s disease centres
(ADC) from across the USA. NACC recruitment and data collection has been described previously [17,
18]. Data included patients seen at ADCs between January 2005 and June 2012. Subjects included in
our study had to be demented and have a diagnosis of probable or possible AD according to
standard diagnostic criteria at the first visit [19]. We generated subsets of this (total AD) group
which excluded those with presence of any other major psychiatric or neurological disorder (AD no
other cause) and which additionally excluded AD subjects with possible AD (probable AD no other
cause) to investigate the robustness of findings.
The study was approved by an institutional review board at each institution. Written informed
consent was obtained from all NACC participants and informants.
55
2.2. Main outcome measures
The outcome measures assessed were the following: (1) first reported predominant cognitive
symptom which included categories: memory; judgment and problem solving; language; visuospatial
function; attention/concentration; “other”; fluctuating cognition; no symptom and “unknown”. (2)
first reported predominant behavioral symptom which included categories: apathy/withdrawal;
depression; psychosis; disinhibition; irritability; agitation; personality change; “other”; REM sleep
behaviour disorder; no symptom and “unknown”. Of note, the “no symptom” categories were
recorded as “not applicable” by NACC. The symptom nominal variables were recorded by the
clinician at the first visit. Specifically, the clinician is asked to indicate which predominant symptom
was the first recognized as a decline in the subject’s cognition and behaviour. Only one cognitive and
one behavioural symptom category was allowed per patient.
2.3. Neuropsychology
Cognitive functioning was assessed using a standardized neuropsychological battery [20] at the same
visit as assessment of first predominant symptoms. Global cognitive functioning was measured using
the mini-mental state examination (MMSE) [21]. From this test, copy of the pentagons was used as a
measure of visuospatial functioning. For memory, we used logical memory story A, parts 1 and 2
from the Wechsler Memory Scale. Attention and working memory were measured using digit span
forward and backward and processing speed by trail making test A and digit symbol from the
Wechsler Adult Intelligence Scale (WAIS). Trail making test B was used to measure executive
functioning. Fluency (animals and vegetables) and the Boston Naming test were used as measures
for language. The number of missing data points varied across tests.
2.4. Statistics
All analyses were performed in Stata SE (version 13). We calculated summary demographic statistics.
We also calculated the proportions of the total AD group who had other psychiatric and neurological
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diagnoses and were excluded from the AD subsets. To investigate memory vs. non-memory
complaints we dichotomized the first cognitive symptom as memory or non-memory for those
subjects who reported a cognitive symptom (i.e. excluding the no symptom and “unknown”
categories). This was used as the dependent variable in binary logistic regression models with age at
first presentation as a continuous predictor variable.
We performed separate multinomial logistic regression analyses to assess the relationship of age at
first presentation (predictor variable) with i) first predominant cognitive symptom and ii) first
predominant behavioral symptom (dependent variables). In our main analyses we considered four
age-bands, specifically <60, 60-69, 70-79 and >79 years. We took the oldest age group and the most
commonly reported symptom (cognitive or behavioral) as the reference groups. In addition, tests
for trend were carried out using models that treated age as a continuous, rather than a categorical,
predictor. Symptom groups with fewer than 10 subjects for any age group were excluded from all
comparisons. For cognitive symptoms these excluded categories were attention/concentration,
“other”, fluctuating cognition, no symptom, and “unknown”. For behavioral symptoms these were
REM sleep disorders and “unknown”. All analyses were first performed in the total AD group, and
then repeated in the AD subsets.
For graphical representation we created plots showing the proportions of first reported
domains/symptoms by age-band. All symptoms, irrespective of group size are represented in these
figures.
For each neuropsychological test we performed a linear regression analysis with age at first
presentation/10 as a continuous predictor and test score as the outcome variable. Resultant
coefficients represent a change in neuropsychological score for a 10 year increase in age of
presentation. All analyses included gender and education as covariates and therefore patients
without recorded educational attainment were excluded from these analyses. Floor (poorest
possible performance) and ceiling (best possible performance) were reported where there were 10
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or more subjects exhibiting these effects. Wald tests of the linear effect of the test score were
performed. For the copy of the pentagons test, where the result was a binary score, the p value
reported is that for this binary predictor. We additionally adjusted for the time between test parts I
and II for the logical memory test part II. Semi-partial R2 values were derived for the relationship
between age and test scores.
Analysis of demographic and genetic variables by first predominant cognitive and behavioral
symptom is presented in the Supplementary Section and Supplementary table 4.
3. Results
3.1 Demographics
Summary demographic information is shown in table 1. On average, patients were 75 years old
when they first presented at the AD Center for their NACC visit but this ranged from 36 to 110 years.
More than half of the patients were female. At first presentation, patients were mildly to
moderately demented (mean (SD) MMSE 19.3 (6.8)). Demographic results were similar in the total
sample and the subsets. The proportions of the total AD group with another psychiatric or
neurological diagnosis are displayed in supplementary table 1.
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Total AD AD no other
cause
Probable AD no
other cause
N 7815 4644 4350
Age at first presentation 75.5 (9.7) [36-
110]
75.7 (9.6) [36-
110]
75.7 (9.5) [36-
102]
Gender, % women 56.2 56.2 56.6
Probable AD, as % of probable and
possible AD
82.6 93.7 100.0
Symptom length, yearsa 5.0 (3.5) 5.0 (3.5) 5.1 (3.5)
Education, yearsb 13.8 (3.9) 14.0 (3.8) 14.0 (3.8)
MMSE at first presentation /30c 19.3 (6.8) 19.3 (6.8) 19.3 (6.8)
Global CDR, % scoring 0, 0.5, 1, 2
and 3
0.2, 28.0, 45.1,
17.5, 9.3
0.0, 29.1, 44.9,
17.0, 9.0
0.0, 28.4, 45.5,
17.1, 8.9
CDR Sum of Boxes, /18 7.0 (4.5) 7.0 (4.4) 7.0 (4.4)
APOE e4 % 0,1,2 allelesd 42.4, 45.4, 12.3 40.2, 46.9, 12.9 39.4, 47.4, 13.2
Positive for APP, PS1, PS2, n 2, 13, 0 0, 8, 0 0, 8, 0
Table 1 Demographic information for the total AD group and subsets.
Mean (SD) and [minimum, maximum] values are shown unless otherwise stated
Data available in all subjects apart from
a: available in 7674 Total AD, 4559 AD no other cause, and 4272 Probable AD no other cause
b: available in 7750 Total AD, 4605 AD no other cause, and 4316 Probable AD no other cause
c: available in 7328 Total AD, 4353 AD no other cause, and 4091 Probable AD no other cause
d: available in 5218 Total AD, 3200 AD no other cause, and 3003 Probable AD no other cause
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3.2. First predominant cognitive and behavioral symptom
The most commonly reported first predominant cognitive symptom was memory (see figure 1). For
those who reported a first cognitive symptom the proportion of AD patients with a non-memory first
predominant cognitive symptom gradually decreased with increasing age: <60 years 26.1%, 60-69
years 19.8%, 70-79 years 10.5%, >79 years 6.3%. In a logistic regression analysis combining all non-
memory cognitive symptom domains the odds of a non-memory first predominant symptom was
multiplied by 1.72 (95% CI 1.61, 1.84, p<0.001) for each ten year decrease in age. Table 2 shows
more detailed results from the multinomial logistic regression analyses that distinguished results for
the non-memory symptom domains. Compared with memory, the odds of having judgment and
problem solving, language and visuospatial problems as the first predominant cognitive symptom all
increased with younger presentation age. These results remained largely unchanged when analyses
were restricted to the AD subsets (see supplementary tables 2 and 3).
<Insert Figure 1 here>
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Age-band <60 years
compared with >79
years
Odds ratio (95% CI)
Age-band 60-69
years compared with
>79 years
Odds ratio (95% CI)
Age-band 70-79
years compared
with >79 years
Odds ratio (95% CI)
Age band >79 years P value from trend
test treating age as
continuous
First predominant
cognitive symptom
compared with
memory
Memory 1.0 1.0 1.0 1.0 reference
Judgement and problem
solving
3.8 (2.6, 5.5) 2.7 (2.0, 3.7) 1.1 (0.8, 1.5) 1.0 <0.001
Language 5.4 (3.5, 8.3) 4.9 (3.4, 7.0) 2.9 (2.1, 4.1) 1.0 <0.001
Visuospatial function 12.1 (7.1, 20.4) 7.6 (4.7, 12.4) 2.3 (1.4, 3.8) 1.0 <0.001
First predominant
behavioral symptom
compared with
Apathy/ withdrawal
Apathy/ withdrawal 1.0 1.0 1.0 1.0 reference
Depression 1.5 (1.2, 1.9) 1.5 (1.3, 1.8) 0.9 (0.8, 1.1) 1.0 <0.001
Psychosis 0.4 (0.2, 0.6) 0.6 (0.4, 0.8) 0.7 (0.5, 0.8) 1.0 <0.001
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Table 2 Relationship between first cognitive/behavioral symptoms with age at first presentation in the total AD group. Odds ratios for first cognitive
symptom and first behavioral symptom are for the younger age-bands compared with the oldest age-band. P values relate to models where age is used as
a continuous variable. Significant results are shown in bold. Odds ratios are represented to 1 decimal place and p values to 1 significant figure.
Disinhibition 0.7 (0.4, 1.3) 0.9 (0.6, 1.4) 0.8 (0.6, 1.1) 1.0 0.3
Irritability 0.9 (0.6, 1.2) 1.0 (0.8, 1.3) 1.2 (1.0, 1.4) 1.0 0.6
Agitation 0.5 (0.3, 1.0) 1.0 (0.7, 1.5) 0.9 (0.7, 1.2) 1.0 0.4
Personality change 1.4 (0.8, 2.5) 1.3 (0.8, 2.1) 1.1 (0.8, 1.6) 1.0 0.1
Other 1.9 (1.2, 3.0) 1.2 (0.8, 1.8) 0.9 (0.6, 1.3) 1.0 0.01
No symptom 0.6 (0.5, 0.8) 0.8 (0.6, 0.9) 0.9 (0.7, 1.0) 1.0 <0.001
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The most commonly reported first behavioral symptom was apathy/withdrawal (see table 2 and
figure 2). Overall, compared with apathy/withdrawal, the odds of having depression and “other”
behavioral symptoms increased with younger presentation age. By contrast, the odds of having
psychosis and no reported symptom increased with older presentation age. Notably, the significant
behavioral findings were typically smaller in magnitude than those seen between presentation age
and cognitive symptoms. These behavioral symptom results remain largely unchanged when analysis
was restricted to the two AD subgroups (see supplementary tables 2 and 3).
<insert Figure 2 here>
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3.3 Neuropsychological results
Results from linear regression analyses relating age at presentation to performance on
neuropsychological tests are shown in Table 3. The table presents the effect of ten year increases in
age on test score adjusted for gender and education. Results showed that older age at presentation
was associated with poorer scores on logical memory tests, trails making tests A and B, digit symbol,
category fluency and Boston Naming Test. For example a ten year increase in age at presentation
was associated with a 0.11 (95% CI 0.02, 0.20) lower logical memory test score. By contrast younger
ages of presentation were associated with reduced ability to copy pentagons and shorter digit spans.
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Domain / skill
assessed
Test N Floor value (N
at floor)
Ceiling value
(N at ceiling)
Change in test score (95% CI)
for ten year increase in age
of presentation
Semi-partial R2 P value
Global cognitive
function
MMSE, /30 7279 0 (144) 30 (62) -0.03
(-0.19,0.13)
<0.0001 0.7
Visuospatial function MMSE pentagon (binary) 2780 NA NA 0.05
(0.03, 0.07)
0.0093 <0.001
Memory Logical memory part I,
/25
6337 0 (1199) NA -0.11
(-0.20, -0.02)
0.0009 0.02
Logical memory part II,
/25
6061 0 (3175) NA -0.25
(-0.33, -0.17)
0.0063 <0.001
Attention and
working memory
Digit span forwards
length, /8
6519 0 (107) 8 (573) 0.18
(0.15, 0.22)
0.0146 <0.001
Digit span backwards
length, /7
6467 0 (347) 7 (88) 0.17
(0.14, 0.21)
0.0152 <0.001
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Processing speed Trails A, 0-150 seconds* 5945 150 (962) NA 1.34
(0.19, 2.48)
0.0008 0.02
WAIS digit symbol, up to
93
5457 0 (226) NA -0.65
(-1.05, -0.25)
0.0017 0.002
Executive functioning Trails B, 0-300 seconds* 4400 300 (1908) NA 7.04
(4.27, 9.80)
0.0054 <0.001
Language Animals, coded up to 77 6569 0 (144) NA -0.54
(-0.67, -0.41)
0.0102 <0.001
Vegetables, coded up to
77
6453 0 (369) NA -0.20
(-0.30, -0.10)
0.0024 <0.001
Boston Naming Test, 30 6371 0 (91) 30 (111) -1.47
(-1.66, -1.28)
0.0331 <0.001
Table 3 Changes in mean age of presentation with neuropsychological tests. Changes in test scores for a ten year increase in age of presentation are
shown together with their 95% CIs. Regression analyses are adjusted for gender and education. Regression analysis for logical memory part II is also
adjusted for time between first and second parts. Semi partial R2 values which represent the amount of variance in test scores explained by presentation
age. *Higher score denotes a poorer performance. NA: not applicable.
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4. Discussion
This study showed that non-memory first symptoms including judgment and problem solving,
language, and visuospatial problems increased gradually with younger presentation of AD. This is
evidenced by higher odds ratios of these non-memory symptoms compared with memory symptoms
in the younger age bands vs. the oldest age band. In addition, younger patients were more likely
than older patients to have a behavioral symptom. Relative to having apathy/withdrawal, depression
and “other” behavioral symptoms increased with younger presentation (higher odds ratios in
younger age bands compared with oldest), whereas psychosis increased with older presentation
(lower odds ratios in younger age bands compared with oldest). Odds ratios were generally higher
for the cognitive symptoms than behavioral symptoms and showed clearer increases per lower age
band for the non-memory cognitive symptoms.
We show that 74% of AD patients presenting at <60 years had a predominant first symptom of
memory problems compared with 92% in those 70 years or over. The proportions of memory vs.
non-memory first symptoms are similar to that of previous studies: one study reported that 68% of
cases under 65 years at onset age had a memory presentation compared with 94% in cases 65 years
and above [7]; another reported that 63% of AD patients with onset <60 years had a memory
presentation [22]. In another single-site study where the average onset was around 60 years, 79% of
cases had typical AD, mild memory problems or an amnestic syndrome as opposed to other focal AD
types [9] which is again in keeping with our findings.
Our data also give weight to smaller neuropsychological studies which have shown that earlier
onsets of AD are associated with more fronto-parietal and less temporal lobe dysfunction [23]. Our
result of a greater proportion of early visuospatial dysfunction at younger ages (7% under 60 years
vs. 1% 70 years and above) replicates other smaller studies which have shown the average age of
those presenting with visual AD subtypes was below 65 years [7-9]. In terms of proportions, one
study found that combined apraxia/visuospatial dysfunction made up 12% of younger onset cases (<
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65 years onset) [7], which is higher than our 7%; unfortunately, apraxia is not recorded by NACC.
Much like our analyses, that study also demonstrated higher proportions of language presentations
at younger onset (9% [7], similar to our 7%). Our study demonstrates that age cut-offs used in
research are arbitrary as non-memory presentations increase with decreasing age.
Our data show that some older AD patients do not have a first symptom of memory dysfunction (8%
of 70+ year olds). Heterogeneity in AD presentations has previously been shown in a selected subset
of NACC data with a study demonstrating dysexecutive and amnestic syndromes with the average
age of these groups being greater than 70 years [10]. Taken together these findings demonstrate AD
heterogeneity remains at older ages, a finding further substantiated by phenotype clustering in AD
subjects over 60 years [24] as well as in selected cohorts such as the Alzheimer’s Disease
Neuroimaging Initiative [25].
Motivation for behavioral symptom research in dementia has increased recently [26, 27]. The
majority of AD patients in our study had a behavioral symptom which is similar, but lower in
proportion, to another study which reported around 90% of AD patients having
behavioral/psychological symptoms [28]. The highest proportions of symptoms in our study were
apathy/withdrawal, depression and irritability which are similar findings to other studies with
respect to analogous symptom categories: one study found apathy, depression and agitation to be
the most frequently reported in late onset AD [29] and another found apathy, irritability and
agitation to be most commonly reported in young onset AD and depression, apathy, irritability and
anxiety in late onset AD [30].
In terms of neuropsychology tests we found that older presenting subjects were more impaired with
respect to memory scores (logical memory parts I and II), processing speed (trail making A, digit
symbol), executive functioning (trail making B) and language (animals and vegetables and Boston
naming test). Younger presenting patients had more problems with attention and working memory
(digit span forwards and backwards) and visuospatial function (pentagons). Despite the fact that
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language problems as a first symptom were associated with younger presentation of AD patients,
the neuropsychology revealed that older subjects were more impaired with respect to language at
first visit. This may be due to the accrual of more language deficits by first visit in older patients
and/or due to the difference in nature between a symptom variable (perception of a problem) and a
neuropsychological test score (relatively objective assessment of one aspect of function).
Our findings are in keeping with others who have assessed identical or modified neuropsychological
tests and their relationships with onset age. Greater language problems with older onsets have
been previously shown (Boston naming test, [32]). Others have demonstrated that those with
younger onset have shorter digit spans [33-35] and poorer performance drawing pentagons [36].
Our results differ from that of two studies which found no significant differences between older or
younger onset cases in any neuropsychological test performed in their study including language,
visuospatial and attention tasks [37, 38]. However, both of these studies were performed using
smaller sample sizes, potentially limiting the power to detect differences. Using identical tests to our
own, one study has shown that processing speed and executive function was worse in younger
subjects (trails A and B [35]) whereas we found older patients performed more poorly in these tests.
Studies investigating onset age in AD and neuropsychological features span the past three decades
and therefore differences between studies’ findings may derive from improved diagnostic criteria
[35] as well as differing disease severities of the populations, power to detect differences, and
covariates used in analyses. Although we have demonstrated significant relationships between
presentation age and neuropsychology, the amount of variance in test scores explained by age was
low, with the highest value being for the Boston Naming Test for which age explained 3% of the
variance.
The findings of our study are congruent with those investigating the relationship between age and
brain morphology and pathology. One autopsy study has demonstrated that hippocampal sparing
AD cases (suggestive of a non-memory presentation) were, on average, younger at onset than
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typical cases [39] and imaging studies have demonstrated relative preservation of the hippocampus/
medial temporal lobe at younger onsets [40-42]. Although the aging process affects widespread
cortical areas including the temporal lobe [43, 44], the areas disproportionately affected by AD and
aging processes differ with temporal areas more affected by AD and fusiform, caudal insula and
medial frontal regions more affected by aging [45]. Therefore, our finding of a higher proportion of
memory (temporal lobe) AD cases with age is partially congruous with the pattern of age-related
changes that can occur. Arguably however, aging in addition to AD would potentially lead to more
non-memory cases occurring at older ages (such as frontal cases) if age-related differences in AD
were driven by a normal aging process applied to a uniform AD process. It is more likely that the
differences we observe in terms of symptoms and age relate in part to predominance of e4 in
memory cases; e4 is an important risk factor for later onset AD [6] and has been shown to drive
atrophy to the medial temporal lobe [46, 47]. Other unknown factors, which cause atrophy outside
of the temporal lobe, non-memory deficits and symptoms, and younger onsets, are also likely to
influence our findings.
The strengths of this study are the large sample size and systematic data collection which enables
more fine-grained analyses of the effects of age on first predominant symptoms. The multi-site
nature of the study improves generalizability of results as compared with single-site studies.
One limitation of this study is the likely noise associated with large cohorts of unselected data; our
results may be in part caused by misdiagnoses, particularly in the non-memory subtypes, as we did
not assess autopsy-confirmed cases. Clinical diagnosis of AD has been shown to be incorrect in 7%-
13% of cases investigated at post mortem [48-50]. Notably, a clinical diagnosis of probable AD in the
NACC neuropathological cohort was shown to have a sensitivity and specificity of 71% compared
with a pathological diagnosis [51]. Biomarker support for AD diagnosis will be an increasingly
important tool in the clinical management of young onset disease where diagnostic accuracy may be
lower. As biomarkers are increasingly used in practice and their interpretations improve, it may be
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that diagnostic accuracy increases with time which will be important to consider in studies where
data collection spans many years. In our study, we performed additional analyses in increasingly
restrictive subsets to minimize the chances of misdiagnoses influencing results. Results remained
largely unaltered, illustrating that symptom heterogeneity is likely to exist in AD. The patients in our
study were from the USA and therefore cultural differences may limit the generalizability of our
results. These differences may manifest in terms of stigma associated with dementia, when to
present to clinic, and the relative importance of specific symptoms. Despite possible differences, we
found similar results to that of European studies which have showed an increased predominance of
non-memory cognitive symptoms at younger onsets [7, 9]. We chose to investigate presentation age
rather than age of cognitive decline which differs from most studies in the literature. This was
chosen as it was more likely to be accurately recorded, was available in more subjects than age of
decline, and our findings are likely to be more relevant to physicians in clinic. Finally, we cannot
exclude the possibility that the first symptoms experienced by AD patients in this study are in part
due to normal aging. Adjustment of our results for those found in controls is not possible using NACC
data since symptoms are not routinely recorded for controls. Further since a proportion of elderly
controls are likely to have underlying AD pathology [52-54], or other neurological conditions,
adjustment for a “normal” aging process is difficult.
A further weakness is the recruitment bias that is likely to be present in this data collection: NACC
data is derived from academic centers which are more likely to have complex and atypical cases
limiting generalizability to community-based patients. Further, subjects had to have a diagnosis of
AD according to NINCDS-ADRDA criteria which requires memory impairment. This means that early
presenting non-memory AD patients may have been excluded leading to an underestimate in their
proportions. Finally, the neuropsychology tests performed do not fully investigate non-memory
domains. For example, the pentagon copy test was the only visuospatial neuropsychological
examination; this test is not a sophisticated or detailed investigation of such deficits. Similarly, the
language tests used may not fully investigate deficits present in younger onset cases. Incorporating
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more non-memory tests into neuropsychological batteries is important, especially if younger
presenting patients attend clinic.
We conclude that presentation age influences first symptoms experienced by clinically-diagnosed AD
patients. Although memory problems are the most common first cognitive symptom experienced at
any age, non-memory symptoms including judgment and problem solving, language, and
visuospatial problems are more prevalent in younger patients. The largest proportion of AD subjects
had apathy/withdrawal as first reported behavioral symptom. Compared with apathy/withdrawal,
depression, and “other” behavioral symptoms increased with younger presentation ages whereas
older subjects were more likely to have psychosis or no behavioral symptom. Importantly, non-
amnestic presentations are acknowledged and behavior is included in the new AD diagnostic criteria
[2]. Appreciation that non-memory first symptoms occur in AD, particularly in younger cases, is
important so that patients have a less tortuous route to diagnosis. Further, non-memory
neuropsychological tests are needed to evaluate the full range of deficits experienced. Better
awareness of non-memory symptoms and more comprehensive testing would allow for improved
services for patients: for example the development of appropriate information materials for those
with visuospatial problems and support services for those who experience behavioural symptoms.
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Figure legends
Figure 1 Age at first presentation and first predominant cognitive symptom.
Percentages are given above colored bars for each symptom group where ≥ 2% 
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Figure 2 Age at first presentation and first predominant behavioral symptom.
Percentages are given above colored bars for each symptom group where ≥ 2% 
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Supplementary Section: Analysis of demographic and genetic variables across first predominant
symptom groups
Methods
Outcome measures
For analysis of demographic and genetic variables across symptom groups we used the following
outcomes: age at presentation, gender, symptom length (the difference between the reported age
of decline in the patient and the age at presentation), educational attainment, mini-mental state
examination (MMSE), clinical dementia rating scale (CDR), CDR sum of boxes, and number of APOE
e4 alleles. We also reported whether there was evidence of familial AD genes (APP, PS1 or PS2). The
number of missing data points varied across measures.
Statistics
For assessment of demographic and genetic variables across the different cognitive and behavioral
symptom groups analyzed in table 2, we performed different analyses depending on the nature of
the outcome variable. For the continuous dependent variables of age at presentation, symptom
length, education, MMSE and CDR sum of boxes we used linear regression analyses with either
cognitive or behavioral symptom groups as the predictor variables. For symptom length we used a
mixed model in order to incorporate Alzheimer’s Disease Center (ADC) as a random effect. For
education we adjusted for gender; for analyses of MMSE and CDR sum of boxes we adjusted for
symptom length, gender and education. All these models, apart from those with age as the outcome
variable, were re-fitted additionally adjusting for age at presentation to assess whether any
differences were independent of age. Where age was the outcome variable, we refitted the models
additionally adjusting for symptom length, where this was recorded, to assess whether differences in
age at presentation, according to symptom groups were due to those with specific symptoms
potentially waiting longer to present to clinic. Where joint Wald tests of differences in these
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continuous outcomes between symptom groups were statistically significant we compared each
symptom group with the memory group (for cognitive symptoms) and the apathy/withdrawal group
(for behavioral symptoms) using the age-adjusted models, or symptom length-adjusted models
where age was the outcome variable.
For CDR and APOE e4 dose we used separate multinomial logistic regression models with CDR score
and number of e4 alleles as outcome variables and either first cognitive or first behavioral symptom
as predictor variables. For CDR we used gender, education and symptom length as covariates. For
gender we used logistic regression with this binary variable as the outcome and either first cognitive
or behavioral symptom as the predictor variable. For these categorical variables of interest (sex, CDR
and number of e4 alleles) we refitted the models additionally using age as a covariate to investigate
whether any differences across groups were independent of age. Likelihood ratio tests were used to
test for differences between groups. Differences in distribution of sex, CDR global score and number
of e4 alleles were assessed using the age-adjusted models with either memory or apathy/withdrawal
as a reference group.
Results
Supplementary table 4 shows basic demographic and genetic summary statistics for cognitive and
behavioral symptom groups. The memory symptom group were older at presentation (p<0.001, all
tests), had a higher proportion of women compared with other groups (p<0.05, all tests) and a lower
proportion of APOE e4 non-carriers (p<0.002, all tests). Those with judgment and problem solving
were more impaired on CDR sum of boxes (p<0.001) and had higher proportions of subjects scoring
2 or 3 on CDR global scores (p<0.03, both tests) compared with memory patients. Compared with
memory patients, the language group had a shorter symptom duration (p=0.01), higher educational
attainment (p<0.001) but were more impaired on MMSE, less impaired on CDR sum of boxes
(p<0.001, both tests), and had a higher proportion of patients scoring 0.5 on global CDR (p<0.001).
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Visuospatial patients had higher educational attainment compared with the memory symptom
group (p<0.001).
For behavioral symptom groups, gender distributions differed with higher proportions of women
seen in the depression, psychosis, agitation, “other” and no symptom groups as compared to apathy
/withdrawal (p<0.05, all tests). Compared with the apathy/withdrawal group those with depression
were younger at presentation, had shorter symptom lengths, were less well educated, less impaired
on the MMSE and CDR sum of boxes (p<0.001, all tests). Further, patients with depression were less
impaired on global CDR: higher proportions scoring 0.5 and lower proportions scoring 2 compared
with apathy and withdrawal (p<0.002, both tests). Those with psychosis were older at presentation,
had lower levels of education, and were more impaired on the MMSE and CDR sum of boxes
(p<0.001, all tests) and had a higher proportion of patients scoring 2 or 3 on global CDR compared
with apathy/withdrawal (p<0.03, both tests). Patients in the disinhibition group had longer symptom
lengths (p=0.02) and were less impaired on the MMSE (p=0.003). Compared with apathy/withdrawal
the irritability group had lower education levels and were less impaired on the MMSE and CDR sum
of boxes and had a higher proportion of patients scoring 0.5 on global CDR (p<0.002, all tests).
Patients with agitation had longer symptom lengths (p=0.03) and were more impaired on the MMSE
and CDR sum of boxes (p<0.001, both tests) and had higher proportions of subjects scoring 2 or 3 on
global CDR (p<0.02, both tests). The “other” group was younger at presentation (p=0.02) whereas
those without behavioral symptoms were older (p<0.001) compared with the apathy/withdrawal
group. However, those with “other” and those with no behavioral symptom had shorter symptom
lengths (p<0.03, both tests) and were less impaired on MMSE and CDR sum of boxes (p<0.003, all
tests). The no symptom group had a larger proportion of patients scoring 0.5 as well as a smaller
proportion of patients scoring 2 and 3 on global CDR (p<0.001, all tests) whereas the “other” group
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had a smaller proportion of patients with a global CDR score 2 only (p=0.05). There was no evidence
of a difference in APOE e4 distribution according to first behavioral symptom.
Discussion
Differences in demographic and genetic variables were seen across the symptom groups. The
greater proportion of females with memory as first symptom is in line with the overall estimates for
AD as a whole [1] as well as with the typical AD group in a separate study [2]. In our current study
the male:female ratio was roughly equal for language much like another study [2] but we reported
an equal male female ratio for the visuospatial group which differed from 70% women reported in
that study [2]. One other smaller study reported no significant difference in gender ratios between
atypical and typical AD cases [3]. We found differences in symptom duration over cognitive
symptom groups which was largely driven by those with language symptoms having shorter
durations (compared to memory) whilst judgment and visuospatial groups were not significantly
different from memory cases. Findings with respect to symptom length / disease durations are
mixed in the literature with some studies showing no difference across AD subtypes [2, 3], one
showing a shorter duration in younger onset AD compared with later onset AD [4], whilst others
show younger onset AD and dementia cases to have longer durations [5, 6] potentially reflecting
convoluted or difficult routes to diagnosis in some settings. The nature of the impairment
experienced by language patients in particular, combined with the increased likelihood of these
cases occurring at a younger age, may indicate rapid referral to ADCs resulting in a shorter symptom
length in these cases. Notably, the language cases are the most impaired (on MMSE) at first visit.
The apparent discrepancy of language symptom cases appearing to be more impaired on MMSE but
less on CDR may be explained by difference in nature of the tests, with MMSE requiring reasonable
language skills and, perhaps, overestimating global impairment in those with prominent language
deficits.
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The lower educational attainment of memory cases is line with what would be expected in older
generations, however we found that this difference remained following adjustment of age at
assessment. A recent study has shown that about half of AD cases are potentially explained by
modifiable risk factors of which low educational attainment was arguably the largest risk factor
worldwide [7] and remained important even within the USA population. It may be that this factor is
important in the largest proportion of AD patients (memory cases) but less important for the less
typical presentations where other factors drive symptoms and age of onset. Genetic factors such as
APOE e4 dose are known to be higher in typical / memory AD cases [8-10] and we found highest
proportions of APOE e4 carriers in the memory group. The lower proportion of e4 carriers in the
visual group is in line findings of others [2, 11] whereas language cases had 57% non-e4 in this study
compared with about 50% in another study [2] and 55% in a smaller language group of mild AD
subjects from NACC defined using neuropsychology tests [12].
Our findings with respect to those with behavioral symptoms being more cognitively impaired are
broadly in line with two studies that found that more severe behavioral symptoms were associated
with more impairment [28, 29]. Our finding that patients with psychosis had greater cognitive
impairment is similar to two previous reports [29, 31]. The lack of evidence we found of a difference
in APOE e4 distribution according to behavioral symptom has been shown previously [29].
Reference List
38
38
1 Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the
public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42.
2 Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, et al. Cognitive
phenotypes in Alzheimer's disease and genetic risk. Cortex 2007;43:835-45.
3 Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, et al. Clinical features
and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurol 2011
17;76:1720-5.
4 Mendez MF, Lee AS, Joshi A, Shapira JS. Nonamnestic presentations of early-onset Alzheimer's
disease. Am J Alzheimers Dis Other Demen 2012;27:413-20.
5 Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early-
versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis 2010;19:1401-8.
6 Shinagawa S, Ikeda M, Toyota Y, Matsumoto T, Matsumoto N, Mori T, et al. Frequency and
clinical characteristics of early-onset dementia in consecutive patients in a memory clinic.
Dement Geriatr Cogn Disord 2007;24:42-7.
7 Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease
prevalence. Lancet Neurol 2011;10:819-28.
8 Mez J, Cosentino S, Brickman AM, Huey ED, Manly JJ, Mayeux R. Dysexecutive Versus Amnestic
Alzheimer Disease Subgroups Analysis of Demographic, Genetic, and Vascular Factors.
Alzheimer Disease & Associated Disorders 2013.
9 Wolk DA, Dickerson BC. Apolipoprotein E (APOE) genotype has dissociable effects on memory
and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A
2010 1;107:10256-61.
39
39
10 van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset
Alzheimer's disease: the case of the missing APOE varepsilon4 allele. Lancet Neurol
2011;10:280-8.
11 Schott JM, Ridha BH, Crutch SJ, Healy DG, Uphill JB, Warrington EK, et al. Apolipoprotein e
genotype modifies the phenotype of Alzheimer disease. Arch Neurol 2006;63:155-6.
12 Mez J, Cosentino S, Brickman AM, Huey ED, Mayeux R. Different Demographic, Genetic, and
Longitudinal Traits in Language versus Memory Alzheimer's Subgroups. J Alzheimers Dis 2013
20.
40
40
41
41
Condition Percentage
Dementia with Lewy bodies 4.0 %
Vascular dementia (NINDS/AIREN Probable) 3.1 %
Vascular dementia (NINDS/AIREN Possible) 1.9 %*
Alcohol-related dementia 0.7 %
Dementia of undetermined etiology 0.6 %
Frontotemporal dementia (behavioral/executive
dementia)
1.9 %
Primary progressive aphasia (aphasic dementia) 1.6 %
Primary progressive
aphasia subtype
Progressive nonfluent aphasia 0.6 % ^
Semantic dementia – anomia plus
word comprehension
0.4 % ^
Semantic dementia – agnosic
variant
<0.1 % ^
Other primary progressive aphasia
(e.g. logopenic, anomic,
transcortical, word deafness,
syntactic comprehension, motor
speech disorder)
0.7 % ^
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Progressive supranuclear palsy 0.1 %
Corticobasal degeneration 0.6 %
Cognitive dysfunction from medications 0.8 %
Cognitive dysfunction from medical illnesses 1.6 %
Parkinson’s disease 1.3 %
Central nervous system neoplasm 0.3 %
Down’s syndrome 0.1 %
Stroke 5.2 %
Hydrocephalus 0.9 %
Depression 21.0 %
Traumatic brain injury 1.4 %
Other major psychiatric illness 1.3 %
Other cognitive/neurologic condition 6.5 %
Supplementary table 1. Proportion of Total AD group with a diagnosis of another neurological or
psychiatric condition in addition to that of possible or probable AD.
*variable not recorded in all subjects. The percentage represents patients with a positive diagnosis
in this category as a proportion of all subjects (n=7815)
^variable recorded in primary progressive aphasia subjects. The percentage represents subjects with
a positive subtype diagnosis as a proportion of all subjects (n=7815).
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Age-band <60
years compared
with >79 years
Odds ratio (95%
CI)
Age-band 60-69
years compared
with >79 years
Odds ratio (95%
CI)
Age-band 70-79
years compared
with >79 years
Odds ratio (95%
CI)
Age band >79
years
P value from
trend test
treating age as
continuous
First predominant
cognitive symptom
compared with
memory
Memory 1.0 1.0 1.0 1.0 reference
Judgement and
problem solving
4.7 (2.8, 8.0) 2.4 (1.5, 4.0) 1.1 (0.7, 1.7) 1.0 <0.001
Language 3.8 (1.9, 7.7) 3.8 (2.2, 6.7) 3.6 (2.2, 5.8) 1.0 <0.001
Visuospatial
function
13.6 (6.4, 28.9) 8.6 (4.2, 17.6) 2.3 (1.1, 4.8) 1.0 <0.001
First predominant
behavioral
Apathy/ withdrawal 1.0 1.0 1.0 1.0 reference
Depression 2.1 (1.4, 3.0) 1.6 (1.2, 2.2) 1.0 (0.8, 1.3) 1.0 <0.001
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Supplementary table 2. Relationship between first cognitive/behavior symptoms with age at first presentation in the AD no other cause group. Odds
ratios for first cognitive symptom and first behavioral symptom for younger age-bands compared with the oldest age-band. P values relate to models
where age is used as a continuous variable. Significant results are shown in bold. Odds ratios are represented to 1 decimal place and p values to 1 significant
figure.
symptom compared
with Apathy/
withdrawal
Psychosis 0.5 (0.2, 0.9) 0.5 (0.3, 0.7) 0.6 (0.5, 0.8) 1.0 <0.001
Disinhibition 0.7 (0.3, 1.5) 0.8 (0.5, 1.4) 0.8 (0.5, 1.1) 1.0 0.3
Irritability 0.9 (0.6, 1.4) 1.1 (0.8, 1.5) 1.2 (1.0, 1.5) 1.0 0.7
Agitation 0.3 (0.1, 0.9) 1.1 (0.7, 1.8) 1.0 (0.7, 1.4) 1.0 0.4
Personality change 1.7 (0.8, 3.7) 1.5 (0.8, 2.9) 1.2 (0.7, 2.0) 1.0 0.03
Other 2.2 (1.2, 4.1) 1.6 (1.0, 2.7) 0.7 (0.4, 1.2) 1.0 0.002
No symptom 0.7 (0.5, 1.0) 0.9 (0.7, 1.1) 0.9 (0.8, 1.1) 1.0 0.02
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Age-band <60
years compared
with >79 years
Odds ratio (95%
CI)
Age-band 60-69
years compared
with >79 years
Odds ratio (95%
CI)
Age-band 70-79
years compared
with >79 years
Odds ratio (95%
CI)
Age band >79
years
P value from
trend test
treating age as
continuous
First predominant
cognitive symptom
compared with
memory
Memory 1.0 1.0 1.0 1.0 reference
Judgement and
problem solving
4.9 (2.8, 8.5) 2.7 (1.6, 4.5) 1.1 (0.6, 1.8) 1.0 <0.001
Language 3.4 (1.6, 7.5) 4.0 (2.2, 7.4) 3.4 (2.0, 5.7) 1.0 <0.001
Visuospatial function 9.8 (4.4, 21.8) 7.0 (3.3, 14.6) 2.1 (1.0, 4.5) 1.0 <0.001
First predominant
behavioral symptom
Apathy/ withdrawal 1.0 1.0 1.0 1.0 reference
Depression 2.0 (1.4, 2.9) 1.6 (1.2, 2.2) 1.0 (0.8, 1.3) 1.0 <0.001
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Supplementary table 3. Relationship between first cognitive/behavior symptoms with age at first presentation in the probable AD no other cause group.
Odds ratios for first cognitive symptom and first behavioral symptom for younger age-bands compared with the oldest age-band. P values relate to models
where age is used as a continuous variable. Significant results are shown in bold. Odds ratios are represented to 1 decimal place and p values to 1 significant
figure.
compared with
Apathy/ withdrawal
Psychosis 0.5 (0.3, 1.0) 0.5 (0.3, 0.8) 0.6 (0.5, 0.9) 1.0 0.001
Disinhibition 0.8 (0.3, 1.8) 0.7 (0.4, 1.3) 0.8 (0.5, 1.2) 1.0 0.3
Irritability 1.0 (0.6, 1.5) 1.2 (0.9, 1.6) 1.3 (1.0, 1.6) 1.0 0.6
Agitation 0.2 (0.0, 0.8) 0.8 (0.5, 1.4) 0.9 (0.6, 1.4) 1.0 0.1
Personality change 1.2 (0.5, 3.1) 1.6 (0.9, 3.1) 1.1 (0.7, 1.9) 1.0 0.1
Other 2.0 (1.0, 3.9) 1.5 (0.8, 2.6) 0.7 (0.4, 1.1) 1.0 0.01
No symptom 0.8 (0.5, 1.1) 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 1.0 0.03
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N
(N
APOE)
Age at first
presentation,
years
Gender,
% women
Symptom
length,
years
Education,
years
MMSE at first
presentation
Global CDR, %
scoring 0, 0.5,
1, 2 and 3
CDR Sum of
Boxes / 18
APOE e4
allele %
0,1,2
n APP,
PS1,
PS2
First predominant
cognitive
symptom
Memory 6914
(4593)
76.2 (9.4) 57.5 5.0 (3.5) 13.7 (4.0) 19.3 (6.7) 0.0, 27.4, 45.7,
17.7, 9,2
7.1 (4.4) 40.8, 46.7,
12.5
2, 13,
0
Judgment and
problem solving
297
(201)
71.6 (11.2) 42.4 5.2 (3.7) 14.3 (3.8) 19.6 (7.0) 0.0, 23.6, 42.4,
22.2, 11.8
7.9 (4.6) 49.8, 35.8,
14.4
0, 0, 0
Language 317
(219)
70.5 (8.8) 46.7 4.3 (3.0) 15.2 (3.2) 18.9 (7.4) 2.8, 43.5, 37.9,
7.6, 8.2
5.5 (4.4) 57.1, 35.2,
7.8
0, 0, 0
Visuospatial
function
178
(134)
67.6 (9.7) 48.3 4.8 (3.0) 15.5 (3.2) 19.7 (7.1) 1.1, 28.1, 45.5,
18.0, 7.3
6.8 (4.3) 56.7, 31.3,
11.9
0, 0, 0
P value for test
across symptom
groups
NA
<0.001
<0.001#
<0.001
<0.001*
0.001~
0.02~~
<0.001^
<0.001^^
0.001**
0.005***
<0.001**
<0.001***
<0.001**
<0.001***
<0.001
<0.001*
NT
First predominant
behavioral
Apathy/
withdrawal
1994
(1339)
75.4 (9.7) 48.1 5.3 (3.6) 14.2 (3.8) 18.6 (6.9) 0.0, 19.1, 48.5,
21.6, 10.9
7.8 (4.4) 41.8, 45.3,
12.9
1, 2, 0
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symptom Depression 1652
(1117)
73.8 (10.6) 65.2 4.8 (3.4) 13.5 (4.1) 19.8 (6.6) 0.2, 29.9, 45.9,
15.6, 8.4
6.7 (4.4) 41.1,
46.6,12.4
1, 6, 0
Psychosis 442
(254)
77.9 (8.9) 63.4 5.1 (3.6) 12.5 (4.1) 16.0 (7.3) 0.0, 12.7, 42.3,
26.9, 18.1
9.1 (4.9) 47.2, 42.9,
9.8
0, 1, 0
Disinhibition 200
(138)
76.1 (9.3) 49.5 5.9 (3.5) 14.2 (4.0) 19.5 (7.2) 0.0, 21.0, 42.0,
26.5,10.5
8.0 (4.5) 40.6, 45.6,
13.8
0, 0, 0
Irritability 960
(622)
75.6 (9.1) 52.0 5.0 (3.6) 13.7 (3.8) 19.5 (6.9) 0.2, 28.9, 44.8,
17.0, 9.2
7.0 (4.4) 43.1, 44.9,
12.1
0, 0, 0
Agitation 233
(162)
75.9 (8.6) 55.4 5.9 (3.3) 13.6 (3.7) 16.0 (8.3) 0.0, 12.9, 35.2,
26.6, 25.3
10.2 (5.3) 40.7, 45.7,
13.6
0, 0, 0
Personality
change
154
(96)
74.0 (10.2) 51.3 5.3 (3.5) 14.0 (3.8) 19.2 (7.6) 0.0, 16.9, 42.2,
26.0, 14.9
8.4 (4.6) 46.9, 41.7,
11.5
0, 0, 0
Other 191
(126)
73.5 (10.6) 67.0 4.6 (3.3) 14.2 (3.7) 20.0 (6.5) 0.0, 28.3, 50.8,
14.1, 6.8
6.5 (4.2) 42.1, 41.3,
16.7
0, 1, 0
No symptom 1841
(1267)
76.7 (9.2) 57.7 4.5 (3.3) 14.1 (3.8) 20.7 (5.9) 0.4, 42.9, 42.9,
10.3, 3.5
5.4 (3.6) 42.8, 46.3,
11.0
0, 3, 0
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Supplementary table 4. Demographic and genetic information for cognitive and behavioral symptom groups
N relates to the maximum number of subjects in each group. Numbers of subjects varies across tests.
# adjusted for symptom length
* adjusted for age
~ adjusted for Alzheimer’s Disease Center
~~ adjusted for Alzheimer’s Disease Center and age
^ adjusted for sex
^^ adjusted for age and sex
** adjusted for sex, symptom length and education level
*** adjusted for age, sex, symptom length and education level
P value for test
across symptom
groups
NA
<0.001
<0.001#
<0.001
<0.001*
<0.001~
<0.001~~
<0.001^
<0.001^^
<0.001**
<0.001***
<0.001**
<0.001***
<0.001**
<0.001***
0.9
>0.9*
NT
